Literature DB >> 2858157

Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy.

R Rizzoli, J Green, S J Marx.   

Abstract

Serum calcium levels were analyzed after one or more explorations for primary hyperparathyroidism in familial multiple endocrine neoplasia type I. These data covered all 85 operations (performed in many hospitals) on 61 of 62 members from 14 kindreds. After 61 initial operations, there were high rates of persistent or recurrent hypercalcemia (54 percent) and chronic hypocalcemia (10 percent). These rates contrast with lower postoperative rates of hypercalcemia (4 to 16 percent) or chronic hypocalcemia (1 to 8 percent) in large series of primary hyperparathyroidism. Persistent or recurrent hypercalcemia after initial exploration decreased only modestly in patients who underwent surgery after 1975 versus before 1975 (46 versus 63 percent). The rate for long-term remission of hypercalcemia after initial parathyroidectomy was higher after a diagnosis of parathyroid hyperplasia was made (as opposed to adenoma) (57 versus 30 percent, p less than 0.05) and after removal of three or more glands (as opposed to removal of two and a half or less) (70 versus 34 percent, p less than 0.01). Following 24 reoperations, there were also high rates of persistent or recurrent hypercalcemia (46 percent) and chronic hypocalcemia (25 percent). After surgery in unselected patients with primary hyperparathyroidism, recurrent hypercalcemia (as opposed to persistent hypercalcemia) is distinctly uncommon; however, it was frequent in familial multiple endocrine neoplasia type I, with total recurrences increasing from 21 percent at five years to 41 percent at 10 years in patients who showed a normocalcemic interval after surgery. The data indicate that the occurrence of persistent or recurrent hypercalcemia after parathyroidectomy in familial multiple endocrine neoplasia type I remains frequent. Although recurrent hypercalcemia may be characteristic of the response to any technique of parathyroidectomy in familial multiple endocrine neoplasia type I and not preventable, persistent hypercalcemia can be decreased by preoperative recognition of the specific familial cause, involvement of an experienced surgical team, and histologic confirmation of the identification of three or more parathyroid glands.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858157     DOI: 10.1016/0002-9343(85)90340-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

Review 1.  Multiple endocrine neoplasia type 1.

Authors:  M L Brandi
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?

Authors:  Naris Nilubol; Lee Weinstein; William F Simonds; Robert T Jensen; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Stephen Marx; Electron Kebebew
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

3.  Controversies and advances in primary hyperparathyroidism.

Authors:  J A Norton
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

Review 4.  Multiple endocrine neoplasia type I: general features and new insights into etiology.

Authors:  M L Brandi
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

5.  Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.

Authors:  Maria D Balsalobre Salmeron; Jose Manuel Rodriguez Gonzalez; Joan Sancho Insenser; Joan Sancho Fornos; Albert Goday; Nuria Maria Torregrosa Perez; Antonio Rios Zambudio; Pascual Parrilla Paricio; Antonio Sitges Serra
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

6.  Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: choice of surgical procedure.

Authors:  J Malmaeus; L Benson; H Johansson; S Ljunghall; J Rastad; G Akerström; K Oberg
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

7.  Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1).

Authors:  Terry C Lairmore; Linda D Piersall; Mary K DeBenedetti; William G Dilley; Matthew G Mutch; Alison J Whelan; Barbara Zehnbauer
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

8.  Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor.

Authors:  T D'Adda; A Amorosi; G Bussolati; M L Brandi; C Bordi
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

9.  Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1.

Authors:  P Hellman; B Skogseid; C Juhlin; G Akerström; J Rastad
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.

Authors:  Anathea C Powell; H Richard Alexander; James F Pingpank; Seth M Steinberg; Monica Skarulis; David L Bartlett; Sunita Agarwal; Craig Cochran; Geoffrey Seidel; Douglas Fraker; Marybeth S Hughes; Robert T Jensen; Stephen J Marx; Steven K Libutti
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.